Cargando…

Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific

BACKGROUND: Herpes zoster (HZ) is a prevalent viral disease that inflicts substantial morbidity and associated healthcare and socioeconomic burdens. Current treatments are not fully effective, especially among the most vulnerable patients. Although widely recommended, vaccination against HZ is not r...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Liang-Kung, Arai, Hidenori, Chen, Liang-Yu, Chou, Ming-Yueh, Djauzi, Samsuridjal, Dong, Birong, Kojima, Taro, Kwon, Ki Tae, Leong, Hoe Nam, Leung, Edward M. F., Liang, Chih-Kuang, Liu, Xiaohong, Mathai, Dilip, Pan, Jiun Yit, Peng, Li-Ning, Poblete, Eduardo Rommel S., Poi, Philip J. H., Reid, Stewart, Tantawichien, Terapong, Won, Chang Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353949/
https://www.ncbi.nlm.nih.gov/pubmed/28298208
http://dx.doi.org/10.1186/s12879-017-2198-y
_version_ 1782515233661648896
author Chen, Liang-Kung
Arai, Hidenori
Chen, Liang-Yu
Chou, Ming-Yueh
Djauzi, Samsuridjal
Dong, Birong
Kojima, Taro
Kwon, Ki Tae
Leong, Hoe Nam
Leung, Edward M. F.
Liang, Chih-Kuang
Liu, Xiaohong
Mathai, Dilip
Pan, Jiun Yit
Peng, Li-Ning
Poblete, Eduardo Rommel S.
Poi, Philip J. H.
Reid, Stewart
Tantawichien, Terapong
Won, Chang Won
author_facet Chen, Liang-Kung
Arai, Hidenori
Chen, Liang-Yu
Chou, Ming-Yueh
Djauzi, Samsuridjal
Dong, Birong
Kojima, Taro
Kwon, Ki Tae
Leong, Hoe Nam
Leung, Edward M. F.
Liang, Chih-Kuang
Liu, Xiaohong
Mathai, Dilip
Pan, Jiun Yit
Peng, Li-Ning
Poblete, Eduardo Rommel S.
Poi, Philip J. H.
Reid, Stewart
Tantawichien, Terapong
Won, Chang Won
author_sort Chen, Liang-Kung
collection PubMed
description BACKGROUND: Herpes zoster (HZ) is a prevalent viral disease that inflicts substantial morbidity and associated healthcare and socioeconomic burdens. Current treatments are not fully effective, especially among the most vulnerable patients. Although widely recommended, vaccination against HZ is not routine; barriers in Asia-Pacific include long-standing neglect of adult immunisation and sparse local data. To address knowledge gaps, raise awareness, and disseminate best practice, we reviewed recent data and guidelines on HZ from the Asia-Pacific region. METHODS: We searched PubMed, Scopus, and World Health Organization databases for articles about HZ published from 1994 to 2014 by authors from Australia, China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, New Zealand, the Philippines, Singapore, Taiwan, Thailand, and Vietnam. We selected articles about epidemiology, burden, complications, comorbidities, management, prevention, and recommendations/guidelines. Internet searches retrieved additional HZ immunisation guidelines. RESULTS: From 4007 retrieved articles, we screened-out 1501 duplicates and excluded 1264 extraneous articles, leaving 1242 unique articles. We found guidelines on adult immunisation from Australia, India, Indonesia, Malaysia, New Zealand, the Philippines, South Korea, and Thailand. HZ epidemiology in Asia-Pacific is similar to elsewhere; incidence rises with age and peaks at around 70 years – lifetime risk is approximately one-third. Average incidence of 3–10/1000 person-years is rising at around 5% per year. The principal risk factors are immunosenescence and immunosuppression. HZ almost always causes pain, and post-herpetic neuralgia is its most common complication. Half or more of hospitalised HZ patients have post-herpetic neuralgia, secondary infections, or inflammatory sequelae that are occasionally fatal. These disease burdens severely diminish patients’ quality of life and incur heavy healthcare utilisation. CONCLUSIONS: Several countries have abundant data on HZ, but others, especially in South-East Asia, very few. However, Asia-Pacific countries generally lack data on HZ vaccine safety, efficacy and cost-effectiveness. Physicians treating HZ and its complications in Asia-Pacific face familiar challenges but, with a vast aged population, Asia bears a unique and growing burden of disease. Given the strong rationale for prevention, most adult immunisation guidelines include HZ vaccine, yet it remains underused. We urge all stakeholders to give higher priority to adult immunisation in general and HZ in particular. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-017-2198-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5353949
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53539492017-03-22 Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific Chen, Liang-Kung Arai, Hidenori Chen, Liang-Yu Chou, Ming-Yueh Djauzi, Samsuridjal Dong, Birong Kojima, Taro Kwon, Ki Tae Leong, Hoe Nam Leung, Edward M. F. Liang, Chih-Kuang Liu, Xiaohong Mathai, Dilip Pan, Jiun Yit Peng, Li-Ning Poblete, Eduardo Rommel S. Poi, Philip J. H. Reid, Stewart Tantawichien, Terapong Won, Chang Won BMC Infect Dis Review BACKGROUND: Herpes zoster (HZ) is a prevalent viral disease that inflicts substantial morbidity and associated healthcare and socioeconomic burdens. Current treatments are not fully effective, especially among the most vulnerable patients. Although widely recommended, vaccination against HZ is not routine; barriers in Asia-Pacific include long-standing neglect of adult immunisation and sparse local data. To address knowledge gaps, raise awareness, and disseminate best practice, we reviewed recent data and guidelines on HZ from the Asia-Pacific region. METHODS: We searched PubMed, Scopus, and World Health Organization databases for articles about HZ published from 1994 to 2014 by authors from Australia, China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, New Zealand, the Philippines, Singapore, Taiwan, Thailand, and Vietnam. We selected articles about epidemiology, burden, complications, comorbidities, management, prevention, and recommendations/guidelines. Internet searches retrieved additional HZ immunisation guidelines. RESULTS: From 4007 retrieved articles, we screened-out 1501 duplicates and excluded 1264 extraneous articles, leaving 1242 unique articles. We found guidelines on adult immunisation from Australia, India, Indonesia, Malaysia, New Zealand, the Philippines, South Korea, and Thailand. HZ epidemiology in Asia-Pacific is similar to elsewhere; incidence rises with age and peaks at around 70 years – lifetime risk is approximately one-third. Average incidence of 3–10/1000 person-years is rising at around 5% per year. The principal risk factors are immunosenescence and immunosuppression. HZ almost always causes pain, and post-herpetic neuralgia is its most common complication. Half or more of hospitalised HZ patients have post-herpetic neuralgia, secondary infections, or inflammatory sequelae that are occasionally fatal. These disease burdens severely diminish patients’ quality of life and incur heavy healthcare utilisation. CONCLUSIONS: Several countries have abundant data on HZ, but others, especially in South-East Asia, very few. However, Asia-Pacific countries generally lack data on HZ vaccine safety, efficacy and cost-effectiveness. Physicians treating HZ and its complications in Asia-Pacific face familiar challenges but, with a vast aged population, Asia bears a unique and growing burden of disease. Given the strong rationale for prevention, most adult immunisation guidelines include HZ vaccine, yet it remains underused. We urge all stakeholders to give higher priority to adult immunisation in general and HZ in particular. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-017-2198-y) contains supplementary material, which is available to authorized users. BioMed Central 2017-03-15 /pmc/articles/PMC5353949/ /pubmed/28298208 http://dx.doi.org/10.1186/s12879-017-2198-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Chen, Liang-Kung
Arai, Hidenori
Chen, Liang-Yu
Chou, Ming-Yueh
Djauzi, Samsuridjal
Dong, Birong
Kojima, Taro
Kwon, Ki Tae
Leong, Hoe Nam
Leung, Edward M. F.
Liang, Chih-Kuang
Liu, Xiaohong
Mathai, Dilip
Pan, Jiun Yit
Peng, Li-Ning
Poblete, Eduardo Rommel S.
Poi, Philip J. H.
Reid, Stewart
Tantawichien, Terapong
Won, Chang Won
Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific
title Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific
title_full Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific
title_fullStr Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific
title_full_unstemmed Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific
title_short Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific
title_sort looking back to move forward: a twenty-year audit of herpes zoster in asia-pacific
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353949/
https://www.ncbi.nlm.nih.gov/pubmed/28298208
http://dx.doi.org/10.1186/s12879-017-2198-y
work_keys_str_mv AT chenliangkung lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT araihidenori lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT chenliangyu lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT choumingyueh lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT djauzisamsuridjal lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT dongbirong lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT kojimataro lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT kwonkitae lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT leonghoenam lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT leungedwardmf lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT liangchihkuang lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT liuxiaohong lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT mathaidilip lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT panjiunyit lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT penglining lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT pobleteeduardorommels lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT poiphilipjh lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT reidstewart lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT tantawichienterapong lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific
AT wonchangwon lookingbacktomoveforwardatwentyyearauditofherpeszosterinasiapacific